about
Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug deliveryUnderstanding peroral absorption: regulatory aspects and contemporary approaches to tackling solubility and permeability hurdlesDrug interactions and antiretroviral drug monitoring.Nucleoside transporters and human organic cation transporter 1 determine the cellular handling of DNA-methyltransferase inhibitors.Expression and localization of p-glycoprotein, multidrug resistance protein 4, and breast cancer resistance protein in the female lower genital tract of human and pigtailed macaque.Pharmacogenomics of antimicrobial agents.Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets.Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib.What do drug transporters really do?Short communication: expression of transporters and metabolizing enzymes in the female lower genital tract: implications for microbicide research.P-glycoprotein (ABCB1) activity decreases raltegravir disposition in primary CD4+P-gphigh cells and correlates with HIV-1 viral load.Combination antiretroviral therapy (cART) component ritonavir significantly alters docetaxel exposure.Expression, regulation, and function of drug transporters in cervicovaginal tissues of a mouse model used for microbicide testing.Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors.Neuronal toxicity of efavirenz: a systematic review.Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients.Polyspecific organic cation transporters and their impact on drug intracellular levels and pharmacodynamics.Human organic cation transporter 1 (hOCT1) as a mediator of bendamustine uptake and cytotoxicity in chronic lymphocytic leukemia (CLL) cells.Class-specific relative genetic contribution for key antiretroviral drugs.Downregulation of duodenal SLC transporters and activation of proinflammatory signaling constitute the early response to high altitude in humans.Labeling of Cellular DNA with a Cyclosal Phosphotriester Pronucleotide Analog of 5-ethynyl-2'-deoxyuridine.Antitubercular Agent Delamanid and Metabolites as Substrates and Inhibitors of ABC and Solute Carrier Transporters.Cytotoxic chemotherapy and the evolution of cellular and viral resistance to antiretroviral therapy in HIV- infected individuals with lymphoma.Entecavir Interacts with Influx Transporters hOAT1, hCNT2, hCNT3, but Not with hOCT2: The Potential for Renal Transporter-Mediated Cytotoxicity and Drug-Drug InteractionsA computational study identifies HIV progression-related genes using mRMR and shortest path tracing.The antiretroviral protease inhibitors indinavir and nelfinavir stimulate Mrp1-mediated GSH export from cultured brain astrocytes.Deleterious nonsynonymous single nucleotide polymorphisms in human solute carriers: the first comparison of three prediction methods.Organic cation transporters OCT1 and OCT2 determine the accumulation of lamivudine in CD4 cells of HIV-infected patients.Antiretroviral Therapy and Alcohol Interactions: X-raying Testicular and Seminal Parameters Under the HAART Era.Precision medicine for HIV: where are we?Who Is Who in Adenosine Transport.
P2860
Q28081272-8420DDD7-9054-4E6F-865F-04B33AA5B8CBQ33683206-47FBE412-ED93-4E9D-B099-B84EDC629CE8Q34021173-C0FCCAE4-2CC4-4534-968F-87F4A6C844E5Q34025097-C80672ED-DEE5-4B0A-BB9F-D57958698C75Q34420654-03AFB004-DD38-4683-B27B-D3290D692592Q34977413-39C4DACA-A894-4F8C-8956-3B92663DF983Q35066350-14711CA4-9C62-4874-A640-8E303AEB5903Q36080621-EAF3D53C-05EE-4E3F-9CB7-A1CEACB8CD02Q36571217-B95521EB-6A0D-4A0A-94AE-C13195EAC9DEQ37258318-7D307BB7-9266-48D2-9403-B3E73974292BQ37273923-AE535D8C-301B-4945-B79E-07FC66D88522Q37669678-B80A466B-8347-4AC8-81E9-BEC796BC7ACAQ37716218-37D3450D-495B-45D4-8F94-0536BCB209DEQ38109095-2655D06A-49E1-4D41-A24C-2679B52F6140Q38124394-EDFB2256-E9CD-42AE-81F0-AFB423B93E2DQ38755666-00784522-5FB6-452F-9D8A-7A68AC2B86DDQ38851414-A303FB7F-C76A-4CFD-8C28-C29094945E25Q38920650-8D90618E-AC02-411C-A059-AC5527C2BF83Q38980007-6C23EA9B-67CA-49F1-ABC3-EDEFFFF7CB14Q38980570-7C88DBDE-AC4C-4808-BC87-69229D564CE5Q39064828-480D4FC7-0406-49C8-85B7-39FDAF4AB375Q39883877-6035BF7A-2F75-4FF8-9896-D7F890EE07A8Q40601224-5E81F2E5-6B43-4B56-884A-A3FB1B16E398Q40829113-A1EC7F79-F1AC-4E8E-9C2F-18C67D117699Q42254960-27D52FFB-EC34-4C5A-B584-DC460790AC00Q44176745-2AB551F4-2269-45E6-97AC-E05489483FC2Q44240406-0F332CB0-8E47-4272-BC71-B8782055217FQ46204858-09F9474D-8B4D-418C-B556-CE7A2FCC7A53Q46496164-94EBEF87-295F-4369-9C61-C1FFDD310AB5Q47569821-FA7621CC-9FD4-4AA8-A994-0AC0D2E9B874Q55407351-F1E86761-E54D-4046-8924-A89B72FBA628
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Drug uptake transporters in antiretroviral therapy.
@en
Drug uptake transporters in antiretroviral therapy.
@nl
type
label
Drug uptake transporters in antiretroviral therapy.
@en
Drug uptake transporters in antiretroviral therapy.
@nl
prefLabel
Drug uptake transporters in antiretroviral therapy.
@en
Drug uptake transporters in antiretroviral therapy.
@nl
P2093
P1476
Drug uptake transporters in antiretroviral therapy.
@en
P2093
Gerard Minuesa
Hermann Koepsell
Isabel Huber-Ruano
Marçal Pastor-Anglada
P304
P356
10.1016/J.PHARMTHERA.2011.06.007
P577
2011-07-23T00:00:00Z